PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions - Summary - MDSpire
Advertisement
PI-RADS upgrading as the strongest predictor for the presence of clinically significant prostate cancer in patients with initial PI-RADS-3 lesions
To confirm the presence of clinically significant prostate cancer (csPCa) through imaging and biopsy during follow-up, and to identify clinical and imaging parameters that can predict csPCa.
Key Findings:
19% of patients presented with prostate cancer (PCa) with ISUP 1 in initial biopsy.
sPbx detected more PCa compared to tPbx (83% vs. 54%; p < 0.001).
28 patients showed PI-RADS-upgrading during follow-up, with 21 (60%) having csPCa.
CsPCa detection rates were 3.4% for PI-RADS < 3, 11.6% for PI-RADS 3, 42.3% for PI-RADS 4, and 50% for PI-RADS 5 (p < 0.001).
PI-RADS upgrading to 4 was the only independent predictor for csPCa detection.
Interpretation:
Upgrading of PI-RADS from 3 to 4 is a significant predictor for the presence of csPCa, underscoring the importance of follow-up imaging and biopsy.
Limitations:
Single-center study may limit generalizability; further multicenter studies are needed.
Retrospective design may introduce bias, affecting the reliability of the findings.
Conclusion:
The study emphasizes the role of PI-RADS upgrading as a critical factor in predicting clinically significant prostate cancer in patients with initial PI-RADS 3 lesions.
